Avanos Announces Divestiture of Hyaluronic Acid Product Line to Channel-Markers Medical

Avanos Medical, Inc. (NYSE: AVNS), announced today the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC. https://mma.prnewswire.com/media/713850/Avanos_Logo.jpg This transaction aligns with Avanos' ongoing transformation, which is focused on advancing its strategic segments in Pain Management & Recovery and Specialty Nutrition Systems. The […]

Polaris Declares Regular Cash Dividend

Polaris Inc. (NYSE: PII) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.67 per share payable on September 15, 2025 to shareholders of record at the close of business on September 2, 2025. About PolarisAs the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and

Arthur J. Gallagher & Co. Announces Second Quarter 2025 Financial Results

Arthur J. Gallagher & Co. (NYSE: AJG) today reported its financial results for the quarter ended June30, 2025. Management will host a webcast conference call to discuss these results on Thursday, July 31, 2025 at 5:15 p.m. ET/4:15 p.m. CT. To listen to the call, and for printer-friendly formats of this release and the “CFO

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

(NasdaqGM:LRMR), BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters'

CubeSmart Reports Second Quarter 2025 Results

(NYSE:CUBE), MALVERN, Pa., July 31, 2025 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) today announced its operating results for the three and six months ended June 30, 2025. “The rental season saw modestly better seasonal performance compared to last year as key operating metrics maintained their positive momentum throughout the second quarter and into July,” commented

Ready Capital Corporation Announces Second Quarter 2025 Results and Webcast Call

(NYSE:RC), NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) — Ready Capital Corporation (NYSE: RC) (the “Company”) today announced that the Company will release its second quarter 2025 financial results after the New York Stock Exchange closes on Thursday, August 7, 2025. Management will host a webcast and conference call on Friday, August 8, 2025 at

Healthcare Realty Reports Second Quarter 2025 Results

(NYSE:HR), NASHVILLE, Tenn., July 31, 2025 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced results for the second quarter ended June 30, 2025. SECOND QUARTER 2025 HIGHLIGHTS GAAP Net loss of $(0.45) per share, NAREIT FFO of $0.34 per share, Normalized FFO of $0.41 per share, and FAD of $115.4 million (payout ratio

eXp World Holdings Reports Q2 2025 Results

(NasdaqGM:EXPI), BELLINGHAM, Wash., July 31, 2025 (GLOBE NEWSWIRE) — eXp World Holdings, Inc. (Nasdaq: EXPI), or the “Company”, the holding company for eXp Realty(R), FrameVR.io and SUCCESS(R) Enterprises,, today announced financial results for the second quarter ended June 30, 2025. “eXp was built by agents, for agents and that foundation continues to fuel our momentum,”

Comstock to Host Second Quarter 2025 Earnings and Business Update Webinar

(NYSE MKT:LODE), VIRGINIA CITY, Nev., July 31, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company's Executive Chairman & CEO, Corrado De Gasperis, and CFO, Judd Merrill will be providing an overview of recent financial results and current business updates on Thursday, August 14, 2025,

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

(NASDAQ:CERT), RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by

Scroll to Top